Skip to content

Clinical Study on the Efficacy and Safety of Photobiomodulation Therapy in Controlling Myopia Progression in Children and Adolescents

Clinical Study on the Efficacy and Safety of Photobiomodulation Therapy in Controlling Myopia Progression in Children and Adolescents

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600116529
Enrollment
Unknown
Registered
2026-01-12
Start date
2026-01-17
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia

Interventions

Intervention group:A 1.6mW vision rehabilitation device.
Control group:A 0.001mW vision rehabilitation device.

Sponsors

Shanghai Eye Disease Prevention and Treatment Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
8 Years to 12 Years

Inclusion criteria

Inclusion criteria: (1) Age: 8-12 years old (2) Simple Myopia: In either eye, after cycloplegia, the spherical equivalent is -3.0 D, with astigmatism <= 2.5 D, and anisometropia<= 1.5 D. (3) Monocular Best-Corrected Visual Acuity (BCVA) of 0.8 or better. (4) Normal ocular fundus, or presence of only a tessellated fundus. (5) Ability to provide signed informed consent and comply with the study procedures.

Exclusion criteria

Exclusion criteria: (1) Subjects with other congenital eye diseases, such as congenital cataract or congenital glaucoma. (2) Presence of manifest strabismus or other disorders of binocular vision. (3) Opacities of the refractive media: e.g., corneal opacity, cataract, or status post intraocular lens implantation. (4) Presence of ocular diseases affecting retinal function. (5) Children who have used or are using other myopia control measures (e.g., orthokeratology lenses, atropine) can only be enrolled after discontinuing such treatments for at least three months. (6) Presence of other systemic disorders or abnormalities. (7) Other reasons deemed by the investigator as making the subject unsuitable for participation in the study.

Design outcomes

Primary

MeasureTime frame
Proportion of subjects with rapid axial length progression (=0.2 mm);

Secondary

MeasureTime frame
Proportion of subjects with myopic progression (=0.50 D) in spherical equivalent after cycloplegia;Proportion of subjects exhibiting axial length regression (change from baseline = -0.05 mm) following photobiomodulation therapy;Change in choroidal thickness after receiving photobiomodulation therapy;Changes in cone photoreceptor density;

Countries

China

Contacts

Public ContactXiangui He

Shanghai Eye Disease Prevention and TreatmentCenter

xianhezi@163.com+86 21 5355 5032

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026